Form 4 for ALXO ALX ONCOLOGY HOLDINGS INC
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0001193125-26-060037 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 | 2026-02-17 | ALXO | Lettmann Jason | CEO, Dir | F - Tax | $2.27 | -2,201 | 305.9K | -0.7% | -$4,996 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | F | D | 2,201 | $2.27 | 305,920 | D | — | — | (F2) Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2025. |